Metraipolis › archive › dc_7a3dceb5c0df

Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq — Europe PMC PMID:36300623

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36300623
DOI
10.7554/elife.78550
License (as archived)
CC0-1.0
Archived
2026-10-16T02:45:12.347Z
SHA-256 of the archived text
3a3e274bb7ebb2f360a4f4fe30cc35b145a76ffee5576de7d1bcea4da5dc1f63
Stable URL of this page
https://metraipolis.com/documento/dc_7a3dceb5c0df

How to cite

Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq — Europe PMC PMID:36300623 — Europe PMC (en), https://europepmc.org/article/MED/36300623 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7a3dceb5c0df (Metraipolis archive dc_7a3dceb5c0df, sha256 3a3e274bb7ebb2f360a4f4fe30cc35b145a76ffee5576de7d1bcea4da5dc1f63)
BibTeX
@misc{dc7a3dceb5c0df,
  title = {Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq — Europe PMC PMID:36300623},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36300623},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7a3dceb5c0df; sha256 3a3e274bb7ebb2f360a4f4fe30cc35b145a76ffee5576de7d1bcea4da5dc1f63},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36300623. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Phage immunoprecipitation sequencing (PhIP-seq) allows for unbiased, proteome-wide autoantibody discovery across a variety of disease settings, with identification of disease-specific autoantigens providing new insight into previously poorly understood forms of immune dysregulation. Despite several successful implementations of PhIP-seq for autoantigen discovery, including our previous work (Vazquez et al., 2020), current protocols are inherently difficult to scale to accommodate large cohorts of cases and importantly, healthy controls. Here, we develop and validate a high throughput extension of PhIP-seq in various etiologies of autoimmune and inflammatory diseases, including APS1, IPEX, RAG1/2 deficiency, Kawasaki disease (KD), multisystem inflammatory syndrome in children (MIS-C), and finally, mild and severe forms of COVID-19. We demonstrate that these scaled datasets enable machine-learning approaches that result in robust prediction of disease status, as well as the ability to detect both known and novel autoantigens, such as prodynorphin (PDYN) in APS1 patients, and intestinally expressed proteins BEST4 and BTNL8 in IPEX patients. Remarkably, BEST4 antibodies were also found in two patients with RAG1/2 deficiency, one of whom had very early onset IBD. Scaled PhIP-seq examination of both MIS-C and KD demonstrated rare, overlapping antigens, including CGNL1, as well as several strongly enriched putative pneumonia-associated antigens in severe COVID-19, including the endosomal protein EEA1. Together, scaled PhIP-seq provides a valuable tool for broadly assessing both rare and common autoantigen overlap between autoimmune diseases of varying origins and etiologies.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: eLife, 2022 (prima pubblicazione 2022-10-27).
Identificativi: PMID 36300623 · PMCID PMC9711525 · DOI 10.7554/elife.78550.
Parole chiave degli autori: Human; Inflammation; Autoantibody; autoantigen; immunology; Ipex; Aps1; Phip-seq; Covid-19.
Descrittori MeSH principali: Bacteriophages; Autoimmune Diseases; COVID-19.
Pagina: https://europepmc.org/article/MED/36300623 — https://doi.org/10.7554/elife.78550. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-16T02:26:47.040Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.